Cytovene and Reglan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cytovene (ganciclovir) and Reglan (metoclopramide hydrochloride). Common drug interactions include anaemia among females and cytomegalovirus infection among males.

The phase IV clinical study analyzes what interactions people have when they take Cytovene and Reglan. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Cytovene?

Cytovene has active ingredients of ganciclovir. eHealthMe is studying from 419 Cytovene users. Check the latest studies of Cytovene.

What is Reglan?

Reglan has active ingredients of metoclopramide hydrochloride. It is often used in gastroparesis. eHealthMe is studying from 29,455 Reglan users. Check the latest studies of Reglan.



On Jul, 16, 2026

14 people who take Cytovene and Reglan together, and have interactions are studied.

Cytovene and Reglan drug interactions.

What are the common drug interactions of Cytovene and Reglan, by gender? *:

female:

  1. Anaemia (lack of blood)
  2. Asthenia (weakness)
  3. Diarrhoea
  4. Haematoma (collection of blood outside the blood vessels)
  5. Hypotension (abnormally low blood pressure)
  6. Peripancreatic fluid collection
  7. Renal tubular necrosis (death of kidney tubules)
  8. Staphylococcal infection (an infection with staphylococcus bacteria)
  9. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  10. Blood culture positive

male:

  1. Cytomegalovirus infection
  2. Dehydration (dryness resulting from the removal of water)
  3. Abdominal pain
  4. Duodenitis (inflammation of the duodenum)
  5. Haemoglobin abnormal
  6. Culture urine positive
  7. Gastritis (inflammation of stomach)
  8. Oesophageal ulcer (ulcer of oesophagus)
  9. Retching (strong involuntary effort to vomit)
  10. Klebsiella infection

What are the common drug interactions of Cytovene and Reglan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Anaemia (lack of blood)
  2. Dehydration (dryness resulting from the removal of water)
  3. Diarrhoea
  4. Headache (pain in head)
  5. Injection site erythema (redness at injection site)
  6. Pyrexia (fever)
  7. Rigors (an episode of shaking or exaggerated shivering)
  8. Sinusitis (inflammation of sinus)
  9. White blood cell count decreased

30-39:

  1. Anaemia (lack of blood)
  2. Haematoma (collection of blood outside the blood vessels)
  3. Hypotension (abnormally low blood pressure)
  4. Peripancreatic fluid collection
  5. Staphylococcal infection (an infection with staphylococcus bacteria)
  6. Asthenia (weakness)
  7. Fatigue (feeling of tiredness)
  8. Incision site complication
  9. Post procedural pain

40-49:

  1. Vomiting
  2. Cytomegalovirus infection
  3. Dehydration (dryness resulting from the removal of water)
  4. Klebsiella infection
  5. Oesophageal candidiasis (fungal infection of oesophagus)
  6. Restlessness (not able to rest)
  7. Tremor (trembling or shaking movements in one or more parts of your body)
  8. Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
  9. Blood creatinine increased
  10. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)

50-59:

  1. Asthenia (weakness)
  2. Blood culture positive
  3. Kidney transplant rejection
  4. Renal tubular necrosis (death of kidney tubules)
  5. Urinary tract infection fungal
  6. Wound infection

60+:

  1. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  2. Diarrhoea
  3. Enterococcal bacteraemia (presence of bacteria lactic acid in the blood)
  4. Hepatic ischaemia (liver does not get enough blood or oxygen, causing injury to liver cells)
  5. Neutropenia (an abnormally low number of neutrophils)
  6. Pulmonary oedema (fluid accumulation in the lungs)
  7. Renal tubular necrosis (death of kidney tubules)
  8. Sepsis (a severe blood infection that can lead to organ failure and death)
  9. Serum sickness (hypersensitivity reaction that results from the injection of heterologous or foreign protein or serum)
  10. Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

  1. Renal And Pancreas Transplant Rejection: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Cytovene and Reglan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cytovene and Reglan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cytovene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Reglan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cytovene and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Reglan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ganciclovir and metoclopramide hydrochloride (the active ingredients of Cytovene and Reglan, respectively), and Cytovene and Reglan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: